1 / 6

Cost-Effectiveness Analysis of Coronary Heart Disease Prevention

Study by Reckless et al. in Value in Health (2010) analyzing Markov model for preventing CHD, patient profiles, lifetime costs, and ICERs for ezetimibe-simvastatin. Includes flow chart, summary graphs, and bootstrap replicates.

ssavage
Download Presentation

Cost-Effectiveness Analysis of Coronary Heart Disease Prevention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Reckless J. et al. Value Health 2010;13:726-34

  2. Flow chart for Markov model of cost-effectivenessin preventing coronary heart disease (CHD) Reckless J. et al. Value Health 2010;13:726-34

  3. Descriptive summary of patient profiles by treatment group Reckless J. et al. Value Health 2010;13:726-34

  4. Summary of projected lifetime costs and benefits by treatment and strata* Reckless J. et al. Value Health 2010;13:726-34

  5. Incremental cost-effectiveness ratios (ICERs) for switching to ezetimibe-simvastatin 10/40 mg compared with doubling the statin dose* Reckless J. et al. Value Health 2010;13:726-34

  6. Plot of bootstrap replicates adjusted for baseline risk profile Reckless J. et al. Value Health 2010;13:726-34

More Related